Consistent with this experimental result, this alteration is a polymorphism (rs63750447, up to 2.7% of controls) in East Asia, speaking against a causative role in cancer; on the other hand, it is the most prevalent somatic alteration reported in MLH1 in different tumor entities (110). Here, MLH1 is linked to cancer.